227 related articles for article (PubMed ID: 32502928)
1. Targeting acute myeloid leukemia stem cells: Current therapies in development and potential strategies with new dimensions.
Tan Y; Wu Q; Zhou F
Crit Rev Oncol Hematol; 2020 Aug; 152():102993. PubMed ID: 32502928
[TBL] [Abstract][Full Text] [Related]
2. Targeting acute myeloid leukemia stem cell signaling by natural products.
Siveen KS; Uddin S; Mohammad RM
Mol Cancer; 2017 Jan; 16(1):13. PubMed ID: 28137265
[TBL] [Abstract][Full Text] [Related]
3. The pan-Bcl2 Inhibitor AT101 Activates the Intrinsic Apoptotic Pathway and Causes DNA Damage in Acute Myeloid Leukemia Stem-Like Cells.
Zhang L; Zhou Y; Chen K; Shi P; Li Y; Deng M; Jiang Z; Wang X; Li P; Xu B
Target Oncol; 2017 Oct; 12(5):677-687. PubMed ID: 28710745
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of leukemic stem cells in acute leukemia and potential targeted therapies for their specific eradication.
Hansen Q; Bachas C; Smit L; Cloos J
Cancer Drug Resist; 2022; 5(2):344-367. PubMed ID: 35800375
[TBL] [Abstract][Full Text] [Related]
5. Acute myeloid leukemia: therapeutic targeting of stem cells.
Pabon CM; Abbas HA; Konopleva M
Expert Opin Ther Targets; 2022 Jun; 26(6):547-556. PubMed ID: 35634856
[TBL] [Abstract][Full Text] [Related]
6. Emerging drugs targeting cellular redox homeostasis to eliminate acute myeloid leukemia stem cells.
Costa RGA; Silva SLR; Dias IRSB; Oliveira MS; Rodrigues ACBDC; Dias RB; Bezerra DP
Redox Biol; 2023 Jun; 62():102692. PubMed ID: 37031536
[TBL] [Abstract][Full Text] [Related]
7. Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, in Vitro Mechanistic Studies, and ex Vivo Patient Derived Therapeutic Efficacy.
Guo J; Russell EG; Darcy R; Cotter TG; McKenna SL; Cahill MR; O'Driscoll CM
Mol Pharm; 2017 Mar; 14(3):940-952. PubMed ID: 28146632
[TBL] [Abstract][Full Text] [Related]
8. [New approaches to target leukemia stem cells].
Takenaka K; Akashi K
Nihon Rinsho; 2014 Jun; 72(6):1018-25. PubMed ID: 25016798
[TBL] [Abstract][Full Text] [Related]
9. Hypothesis: Tim-3/galectin-9, a new pathway for leukemia stem cells survival by promoting expansion of myeloid-derived suppressor cells and differentiating into tumor-associated macrophages.
Gao L; Yu S; Zhang X
Cell Biochem Biophys; 2014 Sep; 70(1):273-7. PubMed ID: 24639110
[TBL] [Abstract][Full Text] [Related]
10. Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia.
Laverdière I; Boileau M; Neumann AL; Frison H; Mitchell A; Ng SWK; Wang JCY; Minden MD; Eppert K
Blood Cancer J; 2018 Jun; 8(6):52. PubMed ID: 29921955
[TBL] [Abstract][Full Text] [Related]
11. Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development.
Yao Y; Li F; Huang J; Jin J; Wang H
Exp Hematol Oncol; 2021 Jul; 10(1):39. PubMed ID: 34246314
[TBL] [Abstract][Full Text] [Related]
12. IGFBP7 Induces Differentiation and Loss of Survival of Human Acute Myeloid Leukemia Stem Cells without Affecting Normal Hematopoiesis.
Verhagen HJMP; van Gils N; Martiañez T; van Rhenen A; Rutten A; Denkers F; de Leeuw DC; Smit MA; Tsui ML; de Vos Klootwijk LLE; Menezes RX; Çil M; Roemer MGM; Vermue E; Heukelom S; Zweegman S; Janssen JJWM; Ossenkoppele GJ; Schuurhuis GJ; Smit L
Cell Rep; 2018 Dec; 25(11):3021-3035.e5. PubMed ID: 30540936
[TBL] [Abstract][Full Text] [Related]
13. Understanding of leukemic stem cells and their clinical implications.
Wang X; Huang S; Chen JL
Mol Cancer; 2017 Jan; 16(1):2. PubMed ID: 28137304
[TBL] [Abstract][Full Text] [Related]
14. Attenuation of microRNA-126 expression that drives CD34+38- stem/progenitor cells in acute myeloid leukemia leads to tumor eradication.
de Leeuw DC; Denkers F; Olthof MC; Rutten AP; Pouwels W; Schuurhuis GJ; Ossenkoppele GJ; Smit L
Cancer Res; 2014 Apr; 74(7):2094-105. PubMed ID: 24477595
[TBL] [Abstract][Full Text] [Related]
15. Diminished AHR Signaling Drives Human Acute Myeloid Leukemia Stem Cell Maintenance.
Ly M; Rentas S; Vujovic A; Wong N; Moreira S; Xu J; Holzapfel N; Bhatia S; Tran D; Minden MD; Draper JS; Hope KJ
Cancer Res; 2019 Nov; 79(22):5799-5811. PubMed ID: 31519687
[TBL] [Abstract][Full Text] [Related]
16. CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia.
Iwasaki M; Liedtke M; Gentles AJ; Cleary ML
Cell Stem Cell; 2015 Oct; 17(4):412-21. PubMed ID: 26387756
[TBL] [Abstract][Full Text] [Related]
17. [Progress in the studies of acute myelogenous leukemia stem cell].
Cui JW; Zhang XM; Wang GJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Oct; 11(5):549-52. PubMed ID: 14575558
[TBL] [Abstract][Full Text] [Related]
18. Theragnostic strategies harnessing the self-renewal pathways of stem-like cells in the acute myeloid leukemia.
Bhattacharjee R; Ghosh S; Nath A; Basu A; Biswas O; Patil CR; Kundu CN
Crit Rev Oncol Hematol; 2022 Sep; 177():103753. PubMed ID: 35803452
[TBL] [Abstract][Full Text] [Related]
19. TMIGD2 is an orchestrator and therapeutic target on human acute myeloid leukemia stem cells.
Wang H; Sica RA; Kaur G; Galbo PM; Jing Z; Nishimura CD; Ren X; Tanwar A; Etemad-Gilbertson B; Will B; Zheng D; Fooksman D; Zang X
Nat Commun; 2024 Jan; 15(1):11. PubMed ID: 38167704
[TBL] [Abstract][Full Text] [Related]
20. Acute Myeloid Leukemia Stem Cell Heterogeneity and Its Clinical Relevance.
Karantanos T; Jones RJ
Adv Exp Med Biol; 2019; 1139():153-169. PubMed ID: 31134500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
